You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Epstein-Barr Virus (EBV) nasopharyngeal carcinoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for

Recruiting
  • Nasopharyngeal Carcinoma
  • EBV antibodies test
  • EBV DNA test
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Jul 6, 2022

Nasopharyngeal Cancer, Epstein-Barr Virus Related Carcinoma Trial in Singapore (FDG-PET, Galium-68 DOTATATE)

Recruiting
  • Nasopharyngeal Cancer
  • Epstein-Barr Virus Related Carcinoma
  • FDG-PET
  • Galium-68 DOTATATE
  • Singapore, Singapore
    National Cancer Centre Singapore
Oct 13, 2022

EBV-positive Nasopharyngeal Carcinoma Trial in Guangzhou (Cohort A: 3.0x10^6 CAR-T cells/kg, Cohort B: 9.0x10^6CAR-T cells/kg,

Not yet recruiting
  • EBV-positive Nasopharyngeal Carcinoma
  • Cohort A: 3.0x10^6 CAR-T cells/kg
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 16, 2023

Verification of Harmonization of Plasma Epstein-Barr Virus DNA

Recruiting
  • Nasopharyngeal Carcinoma
  • Plasma EBV DNA qPCR test
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jul 3, 2022

Nasopharyngeal Cancer, Epstein-Barr Virus Related Carcinoma Trial in Stanford (VK-2019)

Recruiting
  • Nasopharyngeal Cancer
  • Epstein-Barr Virus Related Carcinoma
  • Stanford, California
    Stanford University
Mar 31, 2022

Nasopharyngeal Cancer Trial in Shanghai (Toripalimab, Induction chemo and concurrent chemoradiation)

Recruiting
  • Nasopharyngeal Cancer
  • Toripalimab
  • Induction chemotherapy and concurrent chemoradiation
  • Shanghai, Shanghai, China
    Fudan Universtiy Shanghai Cancer Centre
Nov 25, 2022

Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders, EBV+ Associated Lymphoma Trial (tabelecleucel)

Available
  • Epstein-Barr Virus (EBV) Infections
  • +11 more
  • tabelecleucel
  • (no location specified)
Feb 15, 2022

Hodgkin Disease, Non-Hodgkin Lymphoma, Severe Chronic Active Epstein Barr Virus Trial in Houston (MABEL CTLs, Cyclophosphamide,

Recruiting
  • Hodgkin Disease
  • +5 more
  • MABEL CTLs
  • +2 more
  • Houston, Texas
  • +1 more
Jan 13, 2023

Dynamic Changes of Plasma and Urine Metabolites of

Recruiting
  • Nasopharyngeal Carcinoma
  • EBV Infection
  • Proteomics technology and liquid biopsy
  • Guangzhou, Guangdong, China
    Southern medical university
Jan 4, 2023

Nasopharyngeal Cancer, Epstein-Barr Virus Infections Trial in Hong Kong (Recombinant Epstein-Barr Virus (EBV) Vaccine)

Completed
  • Nasopharyngeal Cancer
  • Epstein-Barr Virus Infections
  • Recombinant Epstein-Barr Virus (EBV) Vaccine
  • Hong Kong, Hong Kong
    Department of Clinical Oncology, Prince of Wales Hospital
Jul 26, 2021

Nasopharyngeal Cancer Trial in Hong Kong (Adjuvant chemo (gemcitabine and cisplatin))

Completed
  • Nasopharyngeal Cancer
  • Adjuvant chemotherapy (gemcitabine and cisplatin)
  • Hong Kong, Hong Kong
  • +5 more
Feb 15, 2022

Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma, EBV-Related Leiomyosarcoma Trial in Worldwide (Nanatinostat,

Recruiting
  • Nasopharyngeal Carcinoma
  • +4 more
  • Lynwood, California
  • +20 more
Jul 27, 2022

Epstein Barr Virus Infection in Radiologically Isolated Syndrome

Recruiting
  • Multiple Sclerosis
  • +2 more
  • NO INTERVENTION
  • Nice, France
    Nice University Hospital
Apr 3, 2023

Epstein-Barr Virus Infections, Lymphoma, Lymphoproliferative Disorder Trial run by the NCI (Nivolumab)

Recruiting
  • Epstein-Barr Virus Infections
  • +3 more
  • Nivolumab
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 24, 2023

Immune Function and PD-1 Antibody Therapy Efficacy Predictors on

Recruiting
  • Secondary Hemophagocytic Lymphohistiocytosis
  • Chronic Active Epstein-Barr Virus Infection
  • No intervention
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
May 2, 2023

Nasopharyngeal Carcinoma Trial in Guangzhou (sintilimab, Capecitabine)

Active, not recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Mar 17, 2022

Immunotherapy With Pembrolizumab for Nasopharyngeal Carcinoma Patients Trial in Taiwan (Pembrolizumab)

Terminated
  • Immunotherapy With Pembrolizumab for Nasopharyngeal Carcinoma Patients
  • Changhua, Taiwan
  • +7 more
Apr 5, 2022

Sensitivity of Endoscopy to Detect Nasopharyngeal Carcinoma

Completed
  • Nasopharyngeal Cancinoma (NPC)
    • Guangzhou, China
      Sun Yat-sen University Cancer Center (SYSUCC)
    Dec 10, 2020

    PD-1 Antibody, Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus Trial in Beijing (L-DEP and PD-1 antibody)

    Not yet recruiting
    • PD-1 Antibody
    • +3 more
    • L-DEP and PD-1 antibody
    • Beijing, Beijing, China
      Beijing Friendship Hospital, Capital Medical University
    Mar 8, 2023

    Early Detection of Epstein-Barr Virus Related Disease.

    Active, not recruiting
    • Post-transplant Lymphoproliferative Disorder
    • +8 more
      • Aarhus, Central Region Of Denmark, Denmark
        Aarhus University Hospital
      Dec 12, 2022

      Epstein-Barr Virus Infection, Infectious Mononucleosis, Herpesvirus Trial run by the National Institute of Allergy and

      Not yet recruiting
      • Epstein-Barr Virus Infection
      • +2 more
      • Matrix-M1 Adjuvant
      • +2 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Feb 2, 2023

      Malignant Tumors Trial in Chengdu (EBV mRNA vaccine)

      Recruiting
      • Malignant Tumors
      • EBV mRNA vaccine
      • Chengdu, Sichuan, China
        West China Hospital, Sichuan University
      Jan 27, 2023

      Epstein-Barr Virus Infection moniToring in renAl Transplant

      Recruiting
      • EBV Infection
      • +3 more
      • EBV DNA in whole blood and plasma
      • Aarhus, Central Region Denmark, Denmark
      • +2 more
      Dec 12, 2022

      Secondary Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection Trial in Beijing (Rituximab

      Recruiting
      • Secondary Hemophagocytic Lymphohistiocytosis
      • Chronic Active Epstein-Barr Virus Infection
      • Rituximab Monotherapy
      • Beijing, China
        Zhao Wang
      May 18, 2022

      Epstein-Barr Virus Positive, Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma Trial (Durvalumab,

      Withdrawn
      • Epstein-Barr Virus Positive
      • +6 more
      • (no location specified)
      Oct 22, 2020